Zydus Drug Desidustat Gets China Approval for Anemia

Zydus Lifesciences Secures Key Approval in China

Zydus Lifesciences has announced a significant regulatory achievement, receiving approval from China's National Medical Products Administration (NMPA) for its innovative drug, Desidustat. The oral tablets are intended for the treatment of anaemia associated with Chronic Kidney Disease (CKD). This approval marks a crucial step for the Indian pharmaceutical company in expanding its global footprint and provides a new treatment option for a large patient population in China. The drug will be marketed in the region by its partner, China Medical System Holdings Ltd (CMS).

The Strategic Partnership with CMS

The foundation for this approval was laid in 2020 when Zydus entered into an exclusive licensing agreement with CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS. Under this agreement, CMS gained a royalty-bearing, exclusive, and sub-licensable license to develop, register, manufacture, and commercialize Desidustat in Greater China. This region includes Mainland China, Hong Kong, Macao, and Taiwan. The collaboration was designed to leverage CMS's local expertise to navigate the regulatory landscape and accelerate the drug's path to market.

Understanding Desidustat and Its Mechanism

Desidustat is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PHI) inhibitor. It works by promoting the body's natural process of producing red blood cells, known as erythropoiesis. The drug increases endogenous erythropoietin and improves iron availability by reducing hepcidin. This mechanism effectively addresses anaemia, a common complication for patients suffering from Chronic Kidney Disease. In India, Zydus has been marketing Desidustat under the brand name Oxemia since its launch in 2022, where it has successfully treated over 100,000 patients.

The Path to Chinese Regulatory Approval

The journey from licensing to approval involved rigorous clinical validation. The New Drug Application (NDA) for Desidustat was formally accepted by the NMPA in May 2024, following the successful completion of Phase III clinical trials in China. These trials demonstrated positive and conclusive results, meeting their primary endpoints. The data showed that Desidustat was significantly more effective than a placebo in increasing haemoglobin (Hb) levels in CKD patients.

Key Clinical Trial Data

The Phase III trial results provided strong evidence of the drug's efficacy. A covariance model analysis highlighted the following outcomes:

These results confirmed that patients treated with Desidustat experienced a substantial increase in their haemoglobin levels, while the placebo group saw a slight decrease. The statistical significance of this difference was a key factor in securing the NMPA's approval.

A Significant Market Opportunity

The approval opens the door to a vast and underserved market. It is estimated that more than 120 million people in China are living with Chronic Kidney Disease. Anaemia is a frequent and debilitating complication of CKD, impacting patients' quality of life. As an orally administered tablet, Desidustat offers a convenient alternative to injectable treatments, which is expected to improve patient compliance and adherence to therapy. This addresses a significant unmet need for both dialysis and non-dialysis patients in the country.

Leadership Commentary

Sharvil P. Patel, Managing Director of Zydus Lifesciences, commented on the development, stating, "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally." He previously noted that the collaboration with CMS would accelerate the development and commercialization process of Desidustat in Greater China, a sentiment now validated by the regulatory green light.

What This Means for Zydus

This approval is a major milestone for Zydus Lifesciences. It not only validates the company's research and development capabilities but also strengthens its position as a global pharmaceutical player. The royalty-based revenue stream from the large Chinese market is expected to contribute positively to the company's financials in the coming years. The successful commercialization of Desidustat by CMS will be a key development to watch as the product rolls out across Greater China.